Cavernous Lymphatic Malformation (CLM)

A cavernous lymphatic malformation (CLM) is a slow-flow vascular malformation made of abnormally formed lymphatic channels and cyst-like spaces (often many small “caverns”) that collect lymph fluid. It is not cancer, and it is not an infection. Most CLMs are present from birth, even if the swelling becomes obvious later in childhood or the teen years. They can occur in the head and neck, skin, mouth/tongue, armpit, chest wall, abdomen, or limbs, and they may be microcystic, macrocystic, or mixed (many lesions are mixed). Radiopaedia+3ISSVA+3Boston Children’s Hospital+3

Cavernous lymphatic malformation is a type of birthmark made of swollen lymph vessels that form a soft, rubbery lump under the skin. It is a benign (non-cancer) problem. The lymph vessels are widened and form “cavern”-like spaces filled with clear lymph fluid. This lesion is present from birth, but it may not be noticed until later in childhood when it grows. It often looks skin-coloured, red, or bluish and can appear anywhere on the body, including the tongue, face, neck, limbs, or trunk.DermNet®+1

In cavernous lymphatic malformation, the lymphatic channels did not form or connect properly before birth. Because of this abnormal development, lymph fluid collects in these enlarged spaces instead of flowing away normally. The lesion usually grows slowly, but it can suddenly become bigger if there is bleeding or infection inside it. Even though it can cause cosmetic or functional problems, it does not spread to other organs like a cancer and does not turn into cancer.DermNet®+1

CLMs can cause problems mainly because they take up space and because the fragile abnormal channels can leak, swell, get inflamed, or bleed into the cysts after minor trauma or viral illness. Symptoms often include soft swelling, pain/tenderness, skin or mouth “blister-like” vesicles, repeated enlargement, infection (cellulitis), or functional issues such as trouble speaking, chewing, breathing, vision problems (near the eye), or movement limits (near joints). PMC+3Boston Children’s Hospital+3Compendium Vascular Anomalies+3

Treatment is usually long-term care, not a one-time cure. Many patients need a care plan that mixes: (1) symptom control, (2) image-guided procedures like sclerotherapy, (3) surgery for selected areas, and (4) targeted medicines (especially when the malformation is diffuse, painful, recurrent, or linked to gene pathways such as PIK3CA). PMC+3Boston Children’s Hospital+3Boston Children’s Hospital+3

---

Other names for cavernous lymphatic malformation

Cavernous lymphatic malformation has been described by several names over time. Older textbooks and many case reports use the term cavernous lymphangioma to describe the same lesion. In modern vascular-anomaly classification, “lymphangioma” has largely been replaced by the broader term lymphatic malformation, but the older term is still widely used in practice.DermNet®+1

Cavernous lymphatic malformation is also grouped under slow-flow lymphatic malformations, which are congenital (present at birth) vascular malformations made of abnormal lymphatic sacs. In some articles, especially radiology reports, cavernous lymphangioma may be described as a microcystic or mixed lymphatic malformation, depending on the size of the internal spaces. In the past, many of these lesions were simply called “lymphangioma” without a subtype.ScienceDirect+1

Some authors link cavernous lymphatic malformation with the more general terms “lymphatic malformation of the head and neck,” “lymphatic malformation of the tongue,” or “orbital lymphatic malformation” when it appears in special sites such as the neck, tongue, or around the eye. These are location-based names rather than different diseases. The underlying problem—abnormally formed lymph vessels with dilated spaces—is the same.EPOS+1

---

Types of cavernous lymphatic malformation

Experts usually talk about lymphatic malformations as a whole group and then describe subtypes. Cavernous lymphatic malformation is one of these subtypes.DermNet®+1

Main related types are:

• Cystic hygroma (macrocystic lymphatic malformation) – This type has large fluid-filled spaces (cysts) greater than about 1–2 cm. It often occurs deep in the neck, face, armpit, or chest and can be translucent and soft. Large cystic hygromas may press on the airway and make breathing or swallowing hard.DermNet®+1

• Cavernous lymphangioma (cavernous lymphatic malformation) – This type can appear anywhere on the body. It usually presents as a skin-coloured, red, or bluish rubbery swelling under the skin and may have periods of rapid growth in early childhood. It is often considered a “microcystic” or mixed lesion with many small cavern-like spaces.DermNet®+1

• Lymphangioma circumscriptum (microcystic lymphatic malformation) – This type is made of many tiny lymph-filled blisters on the skin surface, often resembling frogspawn. It commonly affects the shoulders, neck, axillae, limbs, and tongue. It tends to ooze lymph or bleed and can become more obvious at puberty.DermNet®+1

• Mixed lymphatic malformation – Some lesions show both macrocystic and microcystic or cavernous components. In such cases, doctors may classify the lesion as mixed, but the cavernous part still behaves like a cavernous lymphatic malformation and is treated in a similar way.Journal of Pediatrics+1

Causes of cavernous lymphatic malformation

It is important to understand that the main cause is a problem in lymphatic development before birth. Many “causes” below are really genetic changes or associated conditions that increase the chance of this abnormal development, or later factors that make an existing malformation grow or become obvious.

1. Somatic PIK3CA gene mutations
   The strongest known cause of many lymphatic malformations is a somatic (not inherited) activating mutation in the PIK3CA gene in lymphatic endothelial cells. This mutation turns on the PI3K–mTOR pathway, causing abnormal growth and dilatation of lymphatic vessels and formation of macrocystic lesions like cavernous lymphatic malformations. AHA Journals+2PLOS+2

2. Other somatic gene mutations (for example BRAF)
   Some patients with lymphatic malformations do not have a PIK3CA mutation but instead have other activating mutations, such as BRAF variants, which also disturb cell-growth pathways and can lead to overgrowth of lymphatic channels. Cell+1

3. Embryonic lymphatic development errors without identified mutation
   In many cases, no specific mutation is found, but the lesion still arises from a developmental error in how primitive lymph sacs connect to the rest of the lymphatic system during embryonic life. Abnormal cisterns and channels remain sequestered and later become cystic, cavernous spaces. Wikipedia+2Wikipedia+2

4. RASA1 and EPHB4 pathway abnormalities
   Mutations in genes such as RASA1 and EPHB4, which control vascular and lymphatic vessel signaling, are linked to some vascular anomaly syndromes that include lymphatic malformations. Disturbed signaling in this pathway can promote abnormal lymph vessel formation and malformations. Wiley Online Library+2Ovid+2

5. Other candidate genes in PI3K/AKT/mTOR pathways
   Research continues to find additional genes in the PI3K/AKT/mTOR signaling pathway (for example, PIK3CD and others) that may contribute to lymphatic malformations in a subset of patients, suggesting that several molecular routes can lead to similar cavernous lesions. SpringerLink+1

6. Turner syndrome
   Turner syndrome (complete or partial loss of an X chromosome) is strongly associated with large cystic hygromas and other lymphatic malformations in the neck region, likely due to abnormal lymphatic and venous development in the fetus. DermNet®+2Wikipedia+2

7. Down syndrome (trisomy 21)
   Fetuses and infants with Down syndrome have a higher rate of cystic hygroma and related lymphatic malformations, which can present as cavernous neck or axillary lesions. This suggests that chromosomal imbalance can disturb lymphatic vessel formation. DermNet®+2Wikipedia+2

8. Noonan syndrome
   Noonan syndrome is another genetic condition associated with neck cystic hygromas and lymphatic abnormalities. Altered RAS–MAPK signaling in this syndrome can impair lymphatic vessel development and lead to persistent cystic spaces. Wikipedia+1

9. Trisomy 13 and trisomy 18
   Chromosomal disorders such as trisomy 13 and trisomy 18 can also present with fetal cystic hygroma and other lymphatic malformations, again indicating that global chromosomal changes can disrupt lymphatic morphogenesis. Wikipedia+1

10. PIK3CA-related overgrowth syndromes (PROS)
    Conditions like CLOVES syndrome and Klippel–Trénaunay syndrome are part of the PIK3CA-related overgrowth spectrum and often include extensive lymphatic malformations. In these syndromes, widespread mosaic PIK3CA mutations produce both tissue overgrowth and cavernous lymphatic lesions. Bioscientifica+2Wikipedia+2

11. Complex lymphatic anomalies
    Some patients have complex lymphatic anomalies where malformations affect multiple organs and bones. Updated ISSVA classifications list these serious conditions as part of the lymphatic malformation family and they may include cavernous components. LGD Alliance+2PMC+2

12. Mechanical or venous outflow problems in the fetus
    Altered venous return or compression around the neck or mediastinum in early pregnancy may contribute to fluid build-up and cyst formation, explaining why some large cystic hygromas appear during fetal life even before a specific gene change is identified. Wikipedia+1

13. Acquired lymphatic injury after surgery
    While most cavernous lymphatic malformations are congenital, injury or blockage of lymphatic channels after operations can cause acquired lymphangiectasia, which may look similar and sometimes coexist with congenital lesions, worsening swelling. DermNet®+1

14. Radiation-induced lymphatic damage
    Radiotherapy to the neck, chest, or pelvis can scar lymphatic vessels and produce acquired lymphatic dilatation. These changes do not “cause” the original congenital malformation but may create new dilated channels that resemble or complicate lymphatic malformations. DermNet®+1

15. Chronic local infection or inflammation
    Repeated skin or soft-tissue infections around a lymphatic malformation can cause further damage and scarring to lymphatic vessels. This may enlarge existing cavernous spaces, making the lesion more obvious and symptomatic. National Organization for Rare Disorders+2Cincinnati Children’s+2

16. Trauma and bleeding inside the lesion
    Even minor trauma can cause bleeding into the cysts of a lymphatic malformation, which increases pressure and volume and can trigger rapid, painful enlargement of a previously small or unnoticed cavernous lesion. National Organization for Rare Disorders+2Cincinnati Children’s+2

17. Hormonal changes in puberty
    Many patients notice that lymphatic malformations grow or become more symptomatic around puberty, likely because hormonal changes affect vessel permeability and tissue growth, although the exact mechanisms are not fully understood. Wikipedia+1

18. Pregnancy-related volume and hormone shifts
    In adults, pregnancy can increase blood volume and tissue fluid, which may cause existing cavernous lymphatic malformations to enlarge or become more symptomatic, especially in the neck, chest, or pelvis. RSNA Pubs+1

19. Obesity and chronic high tissue pressure
    Excess body weight can impair lymphatic drainage and increase tissue pressure, possibly worsening swelling and functional problems in areas where a cavernous lymphatic malformation already exists. Lurie Children’s Hospital+1

20. Idiopathic (unknown) cause
    In many individuals, no clear gene variant, syndrome, or external factor is found. The lesion is then considered sporadic and idiopathic, meaning we know it comes from abnormal lymphatic development, but the exact trigger remains unknown. Wikipedia+1

---

Symptoms of cavernous lymphatic malformation

1. Soft, spongy or rubbery lump
   The most common symptom is a soft, smooth, or rubbery mass under the skin, often in the neck, face, armpit, trunk, limbs, or tongue. It may feel “squishy” or spongy when gently pressed. Cedars-Sinai+2Lurie Children’s Hospital+2

2. Compressible swelling that refills
   The swelling often flattens slightly when pressed and then slowly refills when the pressure is removed, because lymph fluid is pushed aside and then returns into the cavernous spaces. Medicover Hospitals+2DermNet PRO+2

3. Change in size over time
   Cavernous lymphatic malformations may grow gradually as the child grows, or they may increase and decrease in size during infections, trauma, or hormonal changes, giving a “waxing and waning” pattern. Compendium Vascular Anomalies+1

4. Skin color changes over the lesion
   The skin over the swelling can look normal, or it may appear pale, pink, red, or bluish. Sometimes small clear or blood-tinged blisters (vesicles) appear on the surface, especially when microcystic components are present. DermNet PRO+2DermNet®+2

5. Rapid painful enlargement
   If bleeding occurs inside the cysts, the lesion can suddenly become firm, larger, and painful. This acute change may be mistaken for an infection or tumor and often prompts urgent medical evaluation. National Organization for Rare Disorders+2Nationwide Children’s Hospital+2

6. Swelling and discomfort in nearby tissues
   Large cavernous lesions can stretch the skin and underlying tissues, causing a feeling of heaviness, tightness, or dull pain in the affected area, especially in the limbs or trunk. Lurie Children’s Hospital+2Cincinnati Children’s+2

7. Recurrent skin or soft-tissue infections
   Areas of lymphatic malformation are prone to infection (cellulitis or lymphangitis). Signs include redness, warmth, increased swelling, tenderness, and sometimes fever and malaise. National Organization for Rare Disorders+2Cedars-Sinai+2

8. Leaking of clear or blood-stained fluid
   Small surface vesicles may break and leak clear lymphatic fluid or occasionally blood, which can be messy, lead to crusting, and increase the risk of infection. Cincinnati Children’s+2DermNet PRO+2

9. Breathing problems (airway compression)
   Cavernous lymphatic malformations in the neck or chest can press on the windpipe and cause noisy breathing, wheezing, shortness of breath, or severe breathing difficulty in babies or children. KidsHealth+2Cedars-Sinai+2

10. Trouble swallowing or feeding
    If the lesion involves the tongue, mouth, throat, or upper chest, it may interfere with swallowing, feeding in infants, or cause choking or coughing while eating or drinking. Cedars-Sinai+2Cleveland Clinic+2

11. Speech or voice changes
    Swelling in the tongue, oral cavity, or larynx can change speech clarity, voice quality, or the ability to articulate certain sounds, especially in children with large tongue lesions. Cedars-Sinai+2Cleveland Clinic+2

12. Vision problems
    When the lesion affects the eyelids or the orbit, it may push the eye forward (proptosis), cause double vision, or block part of the visual field, leading to problems with seeing. Cedars-Sinai+2Cleveland Clinic+2

13. Limited movement of a limb or joint
    Large cavernous lymphatic malformations in the arms or legs can restrict joint movement, alter limb shape, or cause discomfort with activity, which may affect walking or using the limb. Lurie Children’s Hospital+2PMC+2

14. Cosmetic and emotional impact
    Visible swellings on the face, neck, or exposed limbs can affect self-esteem, social interaction, and emotional wellbeing, especially in older children and teenagers who are more aware of appearance. Wikipedia+1

15. Rare life-threatening complications
    In severe cases, massive neck or chest lesions can cause critical airway obstruction, and extensive internal lesions can lead to severe infection, bleeding, or fluid loss, making urgent medical care essential. KidsHealth+2Nationwide Children’s Hospital+2

---

Diagnostic tests for cavernous lymphatic malformation

Doctors use a mix of history, examination, and tests to confirm a cavernous lymphatic malformation, see how far it spreads, and plan safe treatment.

Physical examination tests

1. General inspection and palpation of the lump
   The doctor looks at the shape, size, location, and color of the swelling and gently feels it to check if it is soft, compressible, and non-pulsatile, which are typical clues for a lymphatic malformation rather than a solid tumor or high-flow vascular lesion. SingHealth+2Lurie Children’s Hospital+2

2. Skin and mucosa examination
   The skin or mucous membranes over the lesion are examined for small clear or blood-filled blisters, redness, warmth, ulceration, or leaking fluid, which help distinguish lymphatic malformations from other birthmarks or infections. DermNet PRO+2Wikipedia+2

3. Functional examination of nearby structures
   The doctor checks movement of nearby joints, chewing, swallowing, speech, or eye movements depending on the lesion’s site, because cavernous lymphatic malformations can impair function even when they are benign. Cedars-Sinai+2Lurie Children’s Hospital+2

4. Airway and breathing assessment
   For neck and chest lesions, the clinician listens to breathing, looks for noisy breathing or retractions, and may measure oxygen levels to detect early airway compromise caused by mass effect from the malformation. KidsHealth+2Cedars-Sinai+2

Manual tests

5. Transillumination test
   In some cases, a bright light is placed against the swelling to see if light passes through. Fluid-filled cysts of lymphatic malformations often transilluminate, helping to distinguish them from solid tumors or blood-filled lesions. Nicklaus Children’s Hospital+2Wikipedia+2

6. Compression and refill test
   Gently pressing on the mass to see if it flattens and then refills gives a clue that it is made of deformable fluid-filled spaces, which is typical of cavernous lymphatic malformations and helps separate them from stiff solid growths. Medicover Hospitals+2DermNet PRO+2

7. Positional or Valsalva test
   The size of the lesion may be checked in different positions (lying vs sitting) or during straining or crying. Lymphatic malformations can appear larger in certain positions or with increased venous pressure, which supports the diagnosis of a vascular-type lesion. Compendium Vascular Anomalies+2Medicover Hospitals+2

Lab and pathological tests

8. Complete blood count (CBC)
   A CBC can show anemia if there has been chronic bleeding, or a raised white blood cell count if infection is present in or around the malformation. It also helps assess general health before surgery or other procedures. National Organization for Rare Disorders+2ScienceDirect+2

9. Coagulation profile and D-dimer
   For large or complex vascular malformations, doctors may check clotting tests and D-dimer to look for localized intravascular coagulation or other clotting problems that can increase bleeding risk during treatment. ScienceDirect+2Ovid+2

10. Inflammatory markers (CRP, ESR)
    C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be raised when there is infection or significant inflammation in the lesion, helping to decide whether antibiotics or urgent drainage might be needed. National Organization for Rare Disorders+2Cedars-Sinai+2

11. Basic metabolic and organ function tests
    Blood tests of kidney, liver, and electrolyte levels are often done before major surgery or systemic treatments such as sirolimus, to ensure organs can safely handle medicines or anesthesia. ScienceDirect+2ResearchGate+2

12. Genetic testing of lesion tissue
    When available, tissue or fluid from the lymphatic malformation can be tested for somatic mutations in genes like PIK3CA, BRAF, RASA1, or EPHB4. Identifying the mutation can guide targeted therapies and clarify the exact diagnosis. AHA Journals+2PLOS+2

13. Histopathology (biopsy or excision)
    Microscopic examination of removed tissue shows dilated lymphatic channels lined by a single layer of endothelium within the dermis or deeper tissues, confirming a lymphatic malformation and helping to distinguish it from hemangiomas or other tumors. DermNet®+2DermNet PRO+2

Electrodiagnostic tests

14. Nerve conduction studies (NCS)
    If a large cavernous lymphatic malformation compresses nearby nerves and causes numbness or weakness, nerve conduction tests may be used to measure how well electrical signals move along the affected nerves and to plan treatment that protects nerve function. Lurie Children’s Hospital+2Wikipedia+2

15. Electromyography (EMG)
    EMG evaluates the electrical activity of muscles supplied by compressed nerves. In rare cases of limb or facial involvement, it helps show how much muscle function is affected by the mass and whether changes are reversible. Lurie Children’s Hospital+1

Imaging tests

16. Ultrasound of the lesion
    Ultrasound is often the first imaging test. It can show multiple cystic spaces, fluid levels, and sometimes septa inside the lesion. It is painless, does not use radiation, and is very useful in babies and young children. Nationwide Children’s Hospital+2Johns Hopkins Medicine+2

17. Prenatal ultrasound
    Many large cystic lymphatic malformations in the neck or body can be detected during pregnancy on routine fetal ultrasound, allowing early planning for delivery and airway management if needed. University of Rochester Medical Center+2Cedars-Sinai+2

18. Magnetic resonance imaging (MRI)
    MRI with contrast is often the key imaging tool to confirm a lymphatic malformation and map how far it extends through muscles and around vital structures. It shows the fluid-filled cysts and helps distinguish pure lymphatic lesions from mixed vascular anomalies. Johns Hopkins Medicine+2Ovid+2

19. Computed tomography (CT) scan
    CT scans are sometimes used, especially for chest, abdominal, pelvic, or bony lesions. CT can show how the malformation relates to bones and lungs, but because it uses X-rays, doctors try to limit its use in children when MRI is available. Johns Hopkins Medicine+2Nationwide Children’s Hospital+2

20. Lymphoscintigraphy or MR lymphangiography
    In complex or widespread lymphatic disorders, special imaging such as lymphoscintigraphy or MR lymphangiography can trace lymph flow and highlight abnormal channels. These tests are particularly helpful when planning surgery or advanced interventional procedures. RSNA Pubs+2ScienceDirect+2

---

Non-pharmacological treatments (therapies and others)

1) Watchful waiting (active observation).
If the CLM is small and not harming function, doctors may choose observation with scheduled checks. Purpose: avoid unnecessary procedures. Mechanism: many lesions stay stable; care focuses on monitoring growth, pain, infection, and function over time. Boston Children’s Hospital+1

2) Care in a vascular anomalies team.
Purpose: better diagnosis and safer treatment planning. Mechanism: these teams combine interventional radiology, surgery, ENT, dermatology, genetics, and hematology to match the cyst type (micro/macro/mixed) with the right approach. Boston Children’s Hospital+1

3) Ultrasound/MRI-guided treatment planning.
Purpose: map the lesion before procedures. Mechanism: imaging shows cyst size (macro vs micro), depth, and nearby nerves/vessels, which changes the best treatment choice and reduces complications. Radiopaedia+1

4) Compression garments (for limb lesions).
Purpose: reduce swelling and discomfort. Mechanism: gentle external pressure limits fluid pooling and supports lymph return, especially when a CLM overlaps with lymphedema-like swelling. Boston Children’s Hospital+1

5) Manual lymphatic drainage (specialized massage).
Purpose: help fluid move out of swollen tissues. Mechanism: trained techniques guide lymph toward functioning drainage areas; this may reduce heaviness and tightness when swelling is a major symptom. Boston Children’s Hospital+1

6) Skin and wound care (barrier protection).
Purpose: prevent infection and leakage irritation. Mechanism: moisturizing, gentle cleansing, and protective dressings reduce cracking and bacterial entry, especially when there are vesicles that ooze. Boston Children’s Hospital+1

7) Infection prevention plan (cellulitis plan).
Purpose: reduce repeated painful flares. Mechanism: early recognition, fast medical review, and clear “what to do” steps can shorten infection episodes and reduce scarring and swelling. Boston Children’s Hospital+1

8) Pain management strategies (non-drug).
Purpose: reduce chronic pain and improve sleep. Mechanism: cold packs for acute swelling, gentle stretching, pacing activities, and relaxation breathing can lower pain signals and muscle guarding. Boston Children’s Hospital+1

9) Speech/swallow therapy (mouth/tongue CLM).
Purpose: safer swallowing and clearer speech. Mechanism: therapy trains posture, tongue control, and safe swallowing patterns when the lesion affects oral movement or causes irritation. Boston Children’s Hospital+1

10) Airway safety planning (neck/oral lesions).
Purpose: prevent emergencies. Mechanism: families learn warning signs (noisy breathing, fast swelling), where to go quickly, and how the team will protect the airway if sudden enlargement occurs. Boston Children’s Hospital+1

11) Dental/oral hygiene support.
Purpose: reduce bleeding and infection in mouth lesions. Mechanism: careful brushing, non-irritating rinses, and dental follow-up lower gum inflammation that can worsen pain and bleeding. Boston Children’s Hospital+1

12) Laser/ablative care for superficial “blister” vesicles (procedure-based).
Purpose: reduce oozing, bleeding, and irritation on skin/mucosa. Mechanism: targeted energy closes tiny abnormal surface channels; it is often used as control, not a full cure for deep disease. Boston Children’s Hospital+1

13) Image-guided sclerotherapy (core non-surgical therapy).
Purpose: shrink cysts and reduce symptoms. Mechanism: a specialist injects a sclerosant into the malformation to irritate and scar the lining so the space collapses. It is commonly used for lymphatic malformations. Boston Children’s Hospital+2Boston Children’s Hospital+2

14) Multiple staged procedures (planned sessions).
Purpose: safer treatment for large or complex CLM. Mechanism: instead of one aggressive session, staged treatments allow healing, reduce swelling risk, and gradually shrink the lesion. PMC+1

15) Aspiration/drainage of a tense macrocyst (temporary relief).
Purpose: rapid relief of pain/pressure. Mechanism: fluid is removed with a needle; it often refills unless combined with sclerotherapy, but it can help in urgent swelling situations. PMC+1

16) Lifestyle: avoid repeated trauma/pressure on the area.
Purpose: reduce bleeding-into-cyst and flare swelling. Mechanism: micro-injury can trigger inflammation and sudden enlargement; protection and activity adjustment lowers flare frequency. PMC+1

17) Weight management (when limb swelling is present).
Purpose: reduce mechanical strain and swelling. Mechanism: higher weight increases pressure on lymph drainage; healthy habits can reduce edema burden and improve mobility. Radiopaedia+1

18) Psychological support (body image, chronic condition coping).
Purpose: reduce stress and improve quality of life. Mechanism: counseling and peer support help with visible swelling, school/social stress, and long treatment courses. Boston Children’s Hospital+1

19) Genetic evaluation when lesions are extensive or recurrent.
Purpose: find pathway-based causes (example: PIK3CA-related overgrowth). Mechanism: identifying a pathway can open targeted treatment options (like PI3K inhibition) in severe cases. FDA Access Data+2FDA Access Data+2

20) Emergency action plan + medical ID.
Purpose: faster safe care during sudden swelling or bleeding. Mechanism: a written plan (diagnosis, team contact, imaging history, airway risks) helps emergency clinicians act quickly and correctly. Boston Children’s Hospital+1

---

Drug treatments

1) Sirolimus (Rapamune) – mTOR inhibitor.
Long description: Sirolimus is used by vascular-anomaly specialists to reduce pain, swelling, and complication flares in difficult lymphatic malformations, especially diffuse/microcystic disease. Class: mTOR inhibitor. Dosage/time: oral daily; dose is individualized and often guided by blood levels. Purpose/mechanism: slows abnormal vessel growth signaling and inflammation. Side effects: mouth sores, high lipids, infection risk, low blood counts. Boston Children’s Hospital+3FDA Access Data+3PMC+3

2) Everolimus (Afinitor) – mTOR inhibitor.
Long description: Everolimus is a related mTOR blocker sometimes used when mTOR-pathway control is needed and a specialist prefers it. Class: mTOR inhibitor. Dosage/time: oral daily (label varies by indication). Purpose/mechanism: reduces cell growth signals and can calm inflammatory activity in complex vascular anomalies. Side effects: mouth ulcers, infection risk, high lipids, delayed wound healing, blood count changes. FDA Access Data+2Boston Children’s Hospital+2

3) Alpelisib (VIJOICE) – PI3K inhibitor (for PROS).
Long description: Some lymphatic malformations are part of PIK3CA-related overgrowth spectrum (PROS). VIJOICE is FDA-labeled for severe PROS needing systemic therapy. Class: PI3K inhibitor. Dosage/time: once daily with food (age/weight-based per label). Purpose/mechanism: blocks PI3K signaling, which can reduce overgrowth and symptoms in pathway-driven disease. Side effects: high blood sugar, rash, diarrhea. FDA Access Data+2FDA Access Data+2

4) Trametinib (MEKINIST) – MEK inhibitor (pathway-targeted, off-label for some lymphatic anomalies).
Long description: MEK inhibitors are sometimes considered in selected vascular/lymphatic anomalies linked to RAS/MAPK signaling (specialist decision). Class: MEK inhibitor. Dosage/time: oral daily per label (cancer indications). Purpose/mechanism: reduces MAPK pathway signaling that can drive abnormal vessel behavior. Side effects: rash, diarrhea, heart/eye risks; needs close monitoring. FDA Access Data+1

5) Selumetinib (KOSELUGO) – MEK inhibitor (specialist-directed, off-label for lymphatic disease).
Long description: Selumetinib is FDA-labeled for NF1 plexiform neurofibromas, but MEK pathway control is also studied in some vascular anomaly contexts. Class: MEK inhibitor. Dosage/time: typically twice daily (body-surface-area dosing per label). Purpose/mechanism: blocks MEK signaling; may reduce abnormal tissue growth signals. Side effects: GI upset, rash, heart/eye monitoring needs. FDA Access Data+1

6) Bleomycin (BLENOXANE) – antitumor antibiotic used as a sclerosant (off-label intralesional).
Long description: Bleomycin is widely used by interventional radiologists as an injected sclerosant for lymphatic malformations. Class: antitumor antibiotic/sclerosing agent. Dosage/time: injected into cysts in sessions (protocol varies). Purpose/mechanism: irritates lining and causes scarring/collapse of cyst spaces. Side effects: pain, swelling, fever; systemic toxicity is minimized by careful dosing. FDA Access Data+2PMC+2

7) Doxycycline injection – antibiotic used as a sclerosant (off-label intralesional).
Long description: Doxycycline is commonly used for sclerotherapy, especially for macrocystic or mixed lesions. Class: tetracycline antibiotic. Dosage/time: injected into the malformation during image-guided sessions. Purpose/mechanism: causes controlled inflammation and fibrosis of cyst lining so the space shrinks. Side effects: local pain, swelling, fever; specialists manage dosing carefully. FDA Access Data+2PMC+2

8) Sodium tetradecyl sulfate (SOTRADECOL) – detergent sclerosant (off-label in LM).
Long description: Detergent sclerosants can be used in some vascular malformation procedures; choice depends on lesion type and specialist experience. Class: sclerosant (detergent). Dosage/time: injected intralesionally in controlled amounts. Purpose/mechanism: damages endothelial lining leading to closure/scarring. Side effects: local tissue irritation, ulceration if extravasation, allergic reactions. FDA Access Data+2Boston Children’s Hospital+2

9) Polidocanol (Asclera) – detergent sclerosant (off-label in LM).
Long description: Polidocanol is FDA-labeled for certain varicose veins; some centers use similar agents in vascular anomaly work under strict protocols. Class: sclerosant (detergent). Dosage/time: injected in small controlled volumes. Purpose/mechanism: disrupts lining cells so the treated spaces scar down. Side effects: local pain, pigmentation/ulcer risk, rare allergy. FDA Access Data+2Boston Children’s Hospital+2

10) Ethanolamine oleate (Ethamolin) – sclerosant (specialist-directed).
Long description: Ethanolamine oleate is a sclerosing drug FDA-used for variceal work; “sclerosing” action is sometimes discussed in broader interventional practice. Class: sclerosing agent. Dosage/time: clinician-controlled intralesional/targeted use only. Purpose/mechanism: causes chemical irritation and fibrosis to close treated channels. Side effects: pain, ulceration, inflammation; must be used carefully. FDA Access Data+2Ethamolin+2

11) Propranolol (Inderal) – beta-blocker (limited evidence; selected cases).
Long description: Propranolol has case reports/series in lymphatic malformations (not standard first-line). Class: beta-blocker. Dosage/time: oral, divided doses; clinician adjusts to age/response. Purpose/mechanism: may reduce lymph flow and lymphangiogenesis signals in some cases. Side effects: low heart rate, low blood pressure, low blood sugar risk (kids), bronchospasm. FDA Access Data+2PMC+2

12) Prednisone (systemic steroid) – short course for severe inflammation/airway risk (supportive).
Long description: Steroids do not “remove” a CLM, but they can reduce severe inflammatory swelling in urgent situations under medical supervision. Class: corticosteroid. Dosage/time: short course, taper as directed. Purpose/mechanism: reduces inflammatory swelling and immune activation. Side effects: mood change, high sugar, infection risk, stomach irritation. FDA Access Data+2PMC+2

13) Methylprednisolone (Solu-Medrol) – IV steroid for emergency swelling (supportive).
Long description: In hospital, IV steroids may be used when swelling threatens breathing or vision while definitive care is arranged. Class: corticosteroid. Dosage/time: IV dosing depends on severity and weight. Purpose/mechanism: strong anti-inflammatory effect to rapidly reduce edema. Side effects: high sugar, blood pressure changes, infection risk. FDA Access Data+2PMC+2

14) Amoxicillin/clavulanate (Augmentin) – for bacterial infection complications.
Long description: CLMs can get infected (cellulitis/abscess). Antibiotics treat infection, not the malformation itself. Class: beta-lactam antibiotic combination. Dosage/time: oral, course length based on infection severity. Purpose/mechanism: kills susceptible bacteria and expands coverage with clavulanate. Side effects: diarrhea, rash, allergy. FDA Access Data+2PMC+2

15) Clindamycin (Cleocin) – for skin/soft tissue infection, including some MRSA coverage (supportive).
Long description: Used when infection is suspected or confirmed and clindamycin is appropriate for local resistance patterns. Class: lincosamide antibiotic. Dosage/time: oral/IV depending on severity. Purpose/mechanism: blocks bacterial protein synthesis. Side effects: diarrhea and risk of C. difficile colitis. FDA Access Data+2PMC+2

16) Acetaminophen IV (Ofirmev) – fever/pain control around flares or procedures.
Long description: Helps control pain and fever during inflammatory episodes or after procedures, as part of a safe pain plan. Class: analgesic/antipyretic. Dosage/time: IV dosing depends on age/weight and total daily acetaminophen from all sources. Purpose/mechanism: central pain and fever reduction. Side effects: liver toxicity if overdosed. FDA Access Data+2PMC+2

17) Ibuprofen IV (Caldolor) – short-term pain/inflammation control (supportive).
Long description: NSAIDs may be used short-term for pain and inflammation if safe for the patient. Class: NSAID. Dosage/time: IV dosing per hospital protocol. Purpose/mechanism: COX inhibition reduces inflammatory prostaglandins. Side effects: stomach bleeding risk, kidney strain, asthma sensitivity in some patients. FDA Access Data+2PMC+2

18) Tranexamic acid (Lysteda/Cyklokapron) – bleeding control in selected cases (specialist-directed).
Long description: When superficial mucosal lesions bleed repeatedly, antifibrinolytics may be considered by clinicians in selected settings. Class: antifibrinolytic. Dosage/time: oral or IV depending on scenario. Purpose/mechanism: stabilizes clots by blocking fibrin breakdown. Side effects: clot risk in predisposed patients; needs screening. FDA Access Data+2FDA Access Data+2

19) Topical/local anesthetics (lidocaine class) – procedure comfort (supportive).
Long description: Local anesthetics are used around minor procedures, dressing changes, or oral lesion care when appropriate. Class: local anesthetic. Dosage/time: clinician-directed topical/local use. Purpose/mechanism: blocks nerve conduction to reduce pain. Side effects: numbness, rare systemic toxicity if misused. Boston Children’s Hospital+1

20) Peri-procedure medicines (anti-nausea, reflux protection) – supportive care.
Long description: During repeated procedures, supportive medicines may reduce vomiting, protect the stomach, and improve recovery. Class: varies. Dosage/time: short-term as directed. Purpose/mechanism: symptom control so the patient can eat, hydrate, and heal. Side effects: depend on the drug chosen. PMC+1

---

Dietary molecular supplements

1) Vitamin D.
Dose: depends on blood level. Function: supports bone and immune health. Mechanism: acts like a hormone controlling calcium balance and immune signaling. Note: do not megadose; test if possible. PMC+1

2) Omega-3 (EPA/DHA).
Dose: product-specific. Function: may support a healthy inflammatory balance. Mechanism: changes membrane lipids and inflammatory mediator production. Caution: can increase bruising/bleeding tendency in high doses. PMC+1

3) Vitamin C.
Dose: modest daily amounts. Function: skin healing support. Mechanism: needed for collagen formation and antioxidant defense. Caution: very high doses may cause stomach upset. PMC+1

4) Zinc.
Dose: short courses if deficient. Function: wound healing and immune function. Mechanism: enzyme cofactor for tissue repair and immune cell activity. Caution: excess zinc can cause nausea and reduce copper absorption. PMC+1

5) Magnesium.
Dose: dietary first; supplement if needed. Function: muscle/nerve support and sleep quality. Mechanism: supports energy enzymes and neuromuscular function. Caution: excess can cause diarrhea. PMC+1

6) Iron (only if iron-deficient).
Dose: clinician-guided. Function: treats anemia that can worsen fatigue. Mechanism: restores hemoglobin production. Caution: unnecessary iron can be harmful; test first. PMC+1

7) Folate (B9).
Dose: standard daily amounts when diet is low. Function: red blood cell and tissue repair support. Mechanism: DNA synthesis and cell turnover support. Caution: very high doses can hide B12 deficiency. PMC+1

8) Vitamin B12.
Dose: depends on diet/labs. Function: nerve health and blood formation. Mechanism: supports myelin and red blood cell maturation. Caution: generally safe, but treat based on need. PMC+1

9) Probiotics (selected strains).
Dose: product-specific. Function: may reduce antibiotic-associated diarrhea during infection treatment. Mechanism: supports gut microbiome balance. Caution: immunosuppressed patients should ask a doctor first. PMC+1

10) Protein (nutrition supplement/shakes if intake is low).
Dose: based on dietary needs. Function: supports healing and growth. Mechanism: provides amino acids for tissue repair and immune proteins. Caution: choose balanced products; avoid extreme “muscle gain” formulas. PMC+1

---

Drugs for immune support and regenerative care

1) Immune globulin (IVIG/SCIG; example: Gamunex-C).
Use: only if a patient has proven antibody deficiency or special indications. Mechanism: provides pooled antibodies to improve infection defense. Functional goal: fewer severe infections while on complex care. Risks: thrombosis/renal risks in susceptible patients; clinician monitoring is required. U.S. Food and Drug Administration+1

2) Filgrastim (Neupogen) – G-CSF.
Use: for clinically important neutropenia (not common in CLM itself). Mechanism: stimulates bone marrow to make neutrophils. Functional goal: reduce infection risk when neutrophils are low. Risks: bone pain, spleen enlargement (rare serious). FDA Access Data+1

3) Pegfilgrastim (Neulasta) – long-acting G-CSF.
Use: similar purpose to filgrastim in selected cases. Mechanism: longer stimulation of neutrophil production. Functional goal: fewer infections in neutropenia contexts. Risks: bone pain, rare spleen rupture; specialist-only. FDA Access Data+1

4) Palivizumab (Synagis) – RSV monoclonal antibody (prevention).
Use: for certain high-risk infants/children to prevent severe RSV disease (not a CLM treatment, but may be relevant if airway/respiratory risk exists). Mechanism: neutralizes RSV. Functional goal: prevent severe RSV lung infection. Risks: injection reactions. FDA Access Data+1

5) Becaplermin (Regranex) – topical growth factor for chronic wounds.
Use: only for specific wound-healing indications and clinician guidance. Mechanism: platelet-derived growth factor supports granulation tissue and repair. Functional goal: help hard-to-heal ulcers/wounds (not a CLM shrinker). Risks: local reactions; follow label warnings. FDA Access Data+1

6) Palifermin (Kepivance) – keratinocyte growth factor.
Use: FDA-labeled for severe oral mucositis in selected cancer transplant settings; not a standard CLM therapy, but it shows how growth factors can protect mucosal lining in extreme cases. Mechanism: stimulates epithelial repair. Functional goal: faster mucosal recovery. Risks: rash, mouth/tongue changes. FDA Access Data+1

---

Surgeries (procedures and why they are done)

1) Surgical excision (complete removal when small and well-localized).
Why: best chance for cure in a truly localized lesion. Mechanism: removes abnormal tissue directly. Limits: may not be possible if it wraps around nerves, vessels, or vital structures; recurrence can occur if tissue remains. Boston Children’s Hospital+1

2) Debulking surgery (partial removal).
Why: improve function or appearance when full excision is unsafe. Mechanism: reduces bulk to improve breathing, chewing, speech, vision, or movement. Limits: not curative; may need repeat procedures or combined sclerotherapy. Boston Children’s Hospital+1

3) Surgery after sclerotherapy (combined strategy).
Why: sclerotherapy can shrink and soften the lesion so surgery becomes safer. Mechanism: staged care reduces bleeding and reduces injury to nearby structures. Limits: planning is essential; swelling after procedures can be significant. PMC+2PMC+2

4) Airway procedures (selected emergencies).
Why: if a neck/oral CLM threatens breathing, temporary airway protection may be needed. Mechanism: secures airway while inflammation decreases and definitive treatment is delivered. Limits: done only when clinically necessary. PMC+1

5) Laser surgery for superficial mucosal/skin components.
Why: control surface bleeding/oozing vesicles and improve comfort. Mechanism: closes superficial channels; often repeated. Limits: deep disease usually remains; it is symptom-control focused. Boston Children’s Hospital+1

---

Preventions

1. Protect the area from repeated bumps/pressure to reduce bleeding-into-cyst flares. PMC+1

2. Treat skin cracks/oozing early to lower infection risk. Boston Children’s Hospital+1

3. Keep a “cellulitis plan” (what symptoms mean infection, where to go). PMC+1

4. Good oral hygiene for mouth/tongue lesions to reduce inflammation. PMC+1

5. Use compression when advised for limb swelling. Boston Children’s Hospital+1

6. Keep follow-up imaging when symptoms change (new pain, rapid growth). Radiopaedia+1

7. Avoid self-draining or squeezing swelling (raises infection/bleeding risk). PMC+1

8. Ask about vaccines if on immunosuppressive therapy (sirolimus/everolimus). FDA Access Data+2FDA Access Data+2

9. Maintain healthy sleep and nutrition to support healing after procedures. PMC+1

10. Genetic evaluation in severe/multiple lesions to prevent “wrong therapy” and guide targeted options. FDA Access Data+1

---

When to see doctors (urgent vs routine)

Seek urgent care now if there is fast swelling, trouble breathing, noisy breathing, blue lips, new vision problems, severe pain, fever with spreading redness, or uncontrolled bleeding from mouth/skin vesicles. These can signal airway compromise, infection, or bleeding into the lesion that needs rapid treatment. PMC+1

See a specialist soon if the CLM is growing, causing repeated pain, limiting function (speech, swallowing, walking), or causing frequent infections—because options like sclerotherapy, surgery planning, or targeted medicines work best when planned early and safely. Boston Children’s Hospital+2Boston Children’s Hospital+2

---

What to eat and what to avoid

1. Eat: enough protein (eggs, fish, lentils) to support healing after procedures. PMC+1

2. Eat: fruits/vegetables daily for vitamin C and antioxidant support. PMC+1

3. Eat: high-fiber foods to reduce constipation when pain limits movement. PMC+1

4. Eat: soft foods if oral lesions hurt (soups, yogurt, soft rice). Boston Children’s Hospital+1

5. Drink: steady water intake to support recovery and reduce fatigue. PMC+1

6. Avoid: very spicy/acidic foods if mouth lesions bleed or sting. PMC+1

7. Avoid: very hard/crunchy foods if oral vesicles tear easily. PMC+1

8. Limit: high-sugar drinks/foods—especially important if taking alpelisib (blood sugar can rise). FDA Access Data+1

9. Avoid: unregulated “immune booster” products; discuss supplements with the clinician (drug interactions matter). FDA Access Data+1

10. Ask the team: about special diets only if there is chyle leak/lymphatic flow complications (not needed for everyone). PMC+1

FAQs

1) Is cavernous lymphatic malformation cancer?
No. It is a benign (non-cancer) vascular malformation of lymphatic channels. ISSVA+1

2) Is it something you “catch”?
No. CLM is not contagious and is usually developmental (present from birth). Boston Children’s Hospital+1

3) Why does it suddenly grow?
Growth spurts, minor trauma, infection, or bleeding into cysts can cause sudden swelling. PMC+1

4) What is the best first treatment?
It depends on cyst type and location; sclerotherapy is commonly used, while surgery is best for selected localized lesions. Boston Children’s Hospital+2Boston Children’s Hospital+2

5) Does sclerotherapy cure it?
It can greatly shrink symptoms, especially macrocystic parts, but microcystic/diffuse disease may need repeat sessions or combined care. PMC+2PMC+2

6) Why do doctors sometimes avoid complete surgery?
Because CLMs can wrap around nerves/vessels; removing everything may risk function, so staged or partial approaches are safer. Boston Children’s Hospital+1

7) When are medicines like sirolimus used?
Often for diffuse, painful, recurrent, or complicated lymphatic malformations when procedures alone are not enough. PMC+2FDA Access Data+2

8) Is alpelisib used for all CLMs?
No. It is mainly for severe PROS (PIK3CA-related) cases needing systemic therapy, under specialist care. FDA Access Data+1

9) Are these drug uses always FDA-approved for CLM?
Many are off-label (common in rare vascular anomalies) and should be used only by experienced specialists. Boston Children’s Hospital+1

10) Can it come back after treatment?
Yes, recurrence or regrowth can happen, especially in microcystic or mixed lesions; long-term follow-up is normal. Compendium Vascular Anomalies+1

11) What complications should families watch for?
Infection (fever/redness), fast swelling, bleeding, pain spikes, and breathing or vision symptoms based on location. PMC+1

12) What tests are usually used for diagnosis and planning?
Ultrasound and MRI are common for mapping cyst type and depth and guiding procedures. Radiopaedia+1

13) Does propranolol work like it does for infantile hemangioma?
Evidence is limited; there are reports and small studies, but it is not a universal standard for CLM. PMC+2PMC+2

14) Can lifestyle changes replace medical care?
Lifestyle helps prevent flares (trauma avoidance, skin care), but it usually cannot shrink the lesion alone. Boston Children’s Hospital+1

15) What kind of doctor should manage it?
A vascular anomalies clinic/team is ideal because treatment often needs multiple specialties and careful staging. Boston Children’s Hospital+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 14, 2025.